131 related articles for article (PubMed ID: 38855388)
1. Comparing Insulin Prices in the United States to Other Countries: Updated Results Using 2022 Data.
Mulcahy AW; Schwam D
Rand Health Q; 2024 Jun; 11(3):3. PubMed ID: 38855388
[TBL] [Abstract][Full Text] [Related]
2. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
3. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
[TBL] [Abstract][Full Text] [Related]
4. The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies.
Kakani P; Chernew M; Chandra A
J Health Polit Policy Law; 2022 Dec; 47(6):629-648. PubMed ID: 35867538
[TBL] [Abstract][Full Text] [Related]
5. Branded Price Variation in the United States Drug Market, 2010 to 2019.
Levy J; Ippolito B
Value Health; 2021 Sep; 24(9):1237-1240. PubMed ID: 34452701
[TBL] [Abstract][Full Text] [Related]
6. Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
Mattingly TJ; Levy JF; Slejko JF; Onwudiwe NC; Perfetto EM
Pharmacoeconomics; 2018 Sep; 36(9):1093-1099. PubMed ID: 29752675
[TBL] [Abstract][Full Text] [Related]
7. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
Wineinger NE; Zhang Y; Topol EJ
JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
[TBL] [Abstract][Full Text] [Related]
8. Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018.
Van Nuys K; Ribero R; Ryan M; Sood N
JAMA Health Forum; 2021 Nov; 2(11):e213409. PubMed ID: 35977268
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications.
Mattingly TJ; Anderson GF; Levy JF
JAMA Health Forum; 2023 Jun; 4(6):e231317. PubMed ID: 37294584
[TBL] [Abstract][Full Text] [Related]
10. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
[TBL] [Abstract][Full Text] [Related]
11. Insulin prices, availability and affordability: a cross-sectional survey of pharmacies in Hubei Province, China.
Liu C; Zhang X; Liu C; Ewen M; Zhang Z; Liu G
BMC Health Serv Res; 2017 Aug; 17(1):597. PubMed ID: 28836974
[TBL] [Abstract][Full Text] [Related]
12. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
13. Retail prices of essential drugs in Brazil: an international comparison.
Nóbrega Ode T; Marques AR; de Araújo AC; Karnikowski MG; Naves Jde O; Silver LD
Rev Panam Salud Publica; 2007 Aug; 22(2):118-23. PubMed ID: 17976278
[TBL] [Abstract][Full Text] [Related]
14. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
Gross DJ; Schondelmeyer SW; Raetzman SO
Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
[TBL] [Abstract][Full Text] [Related]
15. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
Rome BN; Feldman WB; Desai RJ; Kesselheim AS
JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
[TBL] [Abstract][Full Text] [Related]
16. Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear.
Sarpatwari A; Tessema FA; Zakarian M; Najafzadeh MN; Kesselheim AS
Health Aff (Millwood); 2021 May; 40(5):772-778. PubMed ID: 33939506
[TBL] [Abstract][Full Text] [Related]
17. Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors.
San-Juan-Rodriguez A; Piro VM; Good CB; Gellad WF; Hernandez I
J Manag Care Spec Pharm; 2021 Jan; 27(1):112-117. PubMed ID: 33377437
[No Abstract] [Full Text] [Related]
18. Barriers to Price and Quality Transparency in Health Care Markets.
Rao P; Fischer SH; Vaiana ME; Taylor EA
Rand Health Q; 2022 Jun; 9(3):1. PubMed ID: 35837511
[TBL] [Abstract][Full Text] [Related]
19. Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.
Wouters OJ; Kanavos PG; McKEE M
Milbank Q; 2017 Sep; 95(3):554-601. PubMed ID: 28895227
[TBL] [Abstract][Full Text] [Related]
20. How the United Kingdom Controls Pharmaceutical Prices and Spending: Learning From Its Experience.
Rodwin MA
Int J Health Serv; 2021 Apr; 51(2):229-237. PubMed ID: 33764174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
